[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030

July 2024 | 150 pages | ID: O7643B03AE7EN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 3 Business Days

Oncology Based In-viv%li%CRO Market Growth & Trends

The global oncology based in-viv%li%CRO market size is expected t%li%reach USD 2.37 billion by 2030, according t%li%a new report by Grand View Research, Inc. The market is anticipated t%li%grow at a CAGR of 8.58% over the forecast period. An increase in outsourcing of R&D activities, high demand for advanced medicines, and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from increasing competition due t%li%patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling pharmaceutical companies t%li%seek the aid of such organizations. Hence, it can be predicted that the oncology-based in-viv%li%CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs t%li%perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking t%li%make an entry int%li%a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs, which have been successful in enabling foreign companies t%li%achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected t%li%expand the market in the coming years. For instance, in January 2023, Bruker, an analytical solutions company, acquired a preclinical Switzerland-based CRO Biogenesis t%li%expand its capabilities in preclinical activities.

Oncology Based In-viv%li%CRO Market Report Highlights
    • The solid tumors segment held the largest share of 47.4% owing t%li%the increasing incidence of cancer across the globe, and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
    • Based on solid tumor-based model, patient-derived xenograft is anticipated t%li%register the fastest CAGR of 9.21% over the forecast period
      • North America accounted for the largest global share of 49.97% in 2023, with the major contributions from the U.S., owing t%li%increased funding available in the region. This has boosted research activities. Major pharmaceutical and life sciences companies continue t%li%drive market growth with their established presence in the region
          • Asia Pacific is anticipated t%li%register the fastest CAGR over the forecast period, owing t%li%many developed countries investing in Asia Pacific regions and the various amendments made by the regulatory market t%li%change the clinical trials evaluation standards according t%li%the global platform
CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE

1.1. Market Segmentation & Scope
1.2. Segment Definitions
  1.2.1. Indication
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Objectives
  1.5.1. Objective-1
  1.5.2. Objective-2
  1.5.3. Objective-3
1.6. Research Methodology
1.7. Information Procurement
  1.7.1. Purchased Database
  1.7.2. GVR’s Internal Database
  1.7.3. Secondary Sources
  1.7.4. Primary Research
1.8. Information Or Data Analysis
  1.8.1. Data Analysis Models
1.9. Market Formulation & Validation
1.10. Model Details
  1.10.1. Commodity Flow Analysis
  1.10.2. Parent Market Analysis
1.11. List Of Secondary Sources
1.12. List Of Abbreviations

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

CHAPTER 3. ONCOLOGY BASED IN-VIVO CRO MARKET VARIABLES, TRENDS & SCOPE

3.1. Market Lineage Outlook
  3.1.1. Parent Market Outlook
  3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
  3.2.1. Market Driver Analysis
    3.2.1.1. Accelerating the time to market
    3.2.1.2. Economic efficiency
    3.2.1.3. Increasing mergers and collaborations
    3.2.1.4. Increasing outsourcing of R&D Activities
  3.2.2. Market Restraint Analysis
3.3. Oncology Based In-vivo CRO Market Analysis Tools
  3.3.1. Industry Analysis - Porter’s
    3.3.1.1. Supplier Power
    3.3.1.2. Buyer Power
    3.3.1.3. Substitution Threat
    3.3.1.4. Threat Of New Entrant
    3.3.1.5. Competitive Rivalry
  3.3.2. PESTEL Analysis
  3.3.3. COVID-19 Impact Analysis
  3.3.4. Major Deals & Strategic Alliances Analysis

CHAPTER 4. ONCOLOGY BASED IN-VIVO CRO MARKET: INDICATION ESTIMATES & TREND ANALYSIS

4.1. Oncology Based In-vivo CRO Market, By Indication: Segment Dashboard
4.2. Oncology Based In-vivo CRO Market, By Indication: Movement Analysis
4.3. Oncology Based In-vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
  4.3.1. Blood cancer
    4.3.1.1. Blood Cancer Market, 2018 to 2030 (USD Million)
    4.3.1.2. Syngeneic model
      4.3.1.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
    4.3.1.3. Patient-derived xenograft
      4.3.1.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
    4.3.1.4. Xenograft
      4.3.1.4.1. Xenograft Market, 2018 to 2030 (USD Million)
  4.3.2. Solid tumor
    4.3.2.1. Solid Tumor Market, 2018 to 2030 (USD Million)
    4.3.2.2. Syngeneic model
      4.3.2.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
    4.3.2.3. Patient derived xenograft
      4.3.2.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
    4.3.2.4. Xenograft
      4.3.2.4.1. Xenograft Market, 2018 to 2030 (USD Million)
  4.3.3. Others
    4.3.3.1. Others Market, 2018 to 2030 (USD Million)
    4.3.3.2. Syngeneic model
      4.3.3.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
    4.3.3.3. Patient derived xenograft
      4.3.3.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
    4.3.3.4. Xenograft
      4.3.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)

CHAPTER 5. ONCOLOGY BASED IN-VIVO CRO MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

5.1. Regional Market Share Analysis, 2023 & 2030
5.2. Regional Market Dashboard
5.3. Global Regional Market Snapshot
5.4. North America
  5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  5.4.2. U.S.
    5.4.2.1. Key Country Dynamics
    5.4.2.2. Competitive Scenario
    5.4.2.3. Regulatory Scenario
    5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  5.4.3. Canada
    5.4.3.1. Key Country Dynamics
    5.4.3.2. Competitive Scenario
    5.4.3.3. Regulatory Scenario
    5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  5.4.4. Mexico
    5.4.4.1. Key Country Dynamics
    5.4.4.2. Competitive Scenario
    5.4.4.3. Regulatory Scenario
    5.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030
5.5. Europe
  5.5.1. UK
    5.5.1.1. Key Country Dynamics
    5.5.1.2. Competitive Scenario
    5.5.1.3. Regulatory Scenario
    5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  5.5.2. Germany
    5.5.2.1. Key Country Dynamics
    5.5.2.2. Competitive Scenario
    5.5.2.3. Regulatory Scenario
    5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  5.5.3. France
    5.5.3.1. Key Country Dynamics
    5.5.3.2. Competitive Scenario
    5.5.3.3. Regulatory Scenario
    5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  5.5.4. Italy
    5.5.4.1. Key Country Dynamics
    5.5.4.2. Competitive Scenario
    5.5.4.3. Regulatory Scenario
    5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  5.5.5. Spain
    5.5.5.1. Key Country Dynamics
    5.5.5.2. Competitive Scenario
    5.5.5.3. Regulatory Scenario
    5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  5.5.6. Denmark
    5.5.6.1. Key Country Dynamics
    5.5.6.2. Competitive Scenario
    5.5.6.3. Regulatory Scenario
    5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  5.5.7. Sweden
    5.5.7.1. Key Country Dynamics
    5.5.7.2. Competitive Scenario
    5.5.7.3. Regulatory Scenario
    5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  5.5.8. Norway
    5.5.8.1. Key Country Dynamics
    5.5.8.2. Competitive Scenario
    5.5.8.3. Regulatory Scenario
    5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
5.6. Asia Pacific
  5.6.1. Japan
    5.6.1.1. Key Country Dynamics
    5.6.1.2. Competitive Scenario
    5.6.1.3. Regulatory Scenario
    5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  5.6.2. China
    5.6.2.1. Key Country Dynamics
    5.6.2.2. Competitive Scenario
    5.6.2.3. Regulatory Scenario
    5.6.2.4. China Market Estimates and Forecasts, 2018 - 2030
  5.6.3. India
    5.6.3.1. Key Country Dynamics
    5.6.3.2. Competitive Scenario
    5.6.3.3. Regulatory Scenario
    5.6.3.4. India Market Estimates and Forecasts, 2018 - 2030
  5.6.4. South Korea
    5.6.4.1. Key Country Dynamics
    5.6.4.2. Competitive Scenario
    5.6.4.3. Regulatory Scenario
    5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  5.6.5. Australia
    5.6.5.1. Key Country Dynamics
    5.6.5.2. Competitive Scenario
    5.6.5.3. Regulatory Scenario
    5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  5.6.6. Thailand
    5.6.6.1. Key Country Dynamics
    5.6.6.2. Competitive Scenario
    5.6.6.3. Regulatory Scenario
    5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
5.7. Latin America
  5.7.1. Brazil
    5.7.1.1. Key Country Dynamics
    5.7.1.2. Competitive Scenario
    5.7.1.3. Regulatory Scenario
    5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  5.7.2. Argentina
    5.7.2.1. Key Country Dynamics
    5.7.2.2. Competitive Scenario
    5.7.2.3. Regulatory Scenario
    5.7.2.4. Argentina Market Estimates and Forecasts, 2018 - 2030
5.8. MEA
  5.8.1. South Africa
    5.8.1.1. Key Country Dynamics
    5.8.1.2. Competitive Scenario
    5.8.1.3. Regulatory Scenario
    5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  5.8.2. Saudi Arabia
    5.8.2.1. Key Country Dynamics
    5.8.2.2. Competitive Scenario
    5.8.2.3. Regulatory Scenario
    5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  5.8.3. UAE
    5.8.3.1. Key Country Dynamics
    5.8.3.2. Competitive Scenario
    5.8.3.3. Regulatory Scenario
    5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  5.8.4. Kuwait
    5.8.4.1. Key Country Dynamics
    5.8.4.2. Competitive Scenario
    5.8.4.3. Regulatory Scenario
    5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

CHAPTER 6. COMPETITIVE LANDSCAPE

6.1. Market Participant Categorization
  6.1.1. Innovators
  6.1.2. Market Leaders
  6.1.3. Emerging Players
  6.1.4. Company Market Share Analysis, 2023
6.2. Company Profiles
  6.2.1. Charles River Laboratory (CRL)
    6.2.1.1. Company Overview
    6.2.1.2. Financial Performance
    6.2.1.3. Service Benchmarking
    6.2.1.4. Strategic Initiatives
  6.2.2. ICON Plc
    6.2.2.1. Company Overview
    6.2.2.2. Financial Performance
    6.2.2.3. Service Benchmarking
    6.2.2.4. Strategic Initiatives
  6.2.3. Thermo Fisher Scientific Inc.
    6.2.3.1. Company Overview
    6.2.3.2. Financial Performance
    6.2.3.3. Service Benchmarking
    6.2.3.4. Strategic Initiatives
  6.2.4. Eurofins Scientific
    6.2.4.1. Company Overview
    6.2.4.2. Financial Performance
    6.2.4.3. Service Benchmarking
    6.2.4.4. Strategic Initiatives
  6.2.5. Taconic Biosciences
    6.2.5.1. Company Overview
    6.2.5.2. Financial Performance
    6.2.5.3. Service Benchmarking
    6.2.5.4. Strategic Initiatives
  6.2.6. Crown Bioscience
    6.2.6.1. Company Overview
    6.2.6.2. Financial Performance
    6.2.6.3. Service Benchmarking
    6.2.6.4. Strategic Initiatives
  6.2.7. Lab Corp
    6.2.7.1. Company Overview
    6.2.7.2. Financial Performance
    6.2.7.3. Service Benchmarking
    6.2.7.4. Strategic Initiatives
  6.2.8. WuXi AppTec
    6.2.8.1. Company Overview
    6.2.8.2. Financial Performance
    6.2.8.3. Service Benchmarking
    6.2.8.4. Strategic Initiatives
  6.2.9. EVOTEC
    6.2.9.1. Company Overview
    6.2.9.2. Financial Performance
    6.2.9.3. Service Benchmarking
    6.2.9.4. Strategic Initiatives
  6.2.10. The Jackson Laboratory
    6.2.10.1. Company Overview
    6.2.10.2. Financial Performance
    6.2.10.3. Service Benchmarking
    6.2.10.4. Strategic Initiatives
LIST OF TABLES


Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 North America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 4 North America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 5 U.S. Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 6 Canada Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 7 Mexico Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 8 Europe Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 9 Europe Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 10 UK Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 11 Germany Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 12 France Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 13 Italy Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 14 Spain Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 15 Denmark Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 16 Sweden Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 17 Norway Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 18 Asia Pacific Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 19 Asia Pacific Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 20 Japan Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 21 China Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 22 India Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 23 South Korea Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 24 Australia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 25 Thailand Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 26 Latin America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 27 Latin America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 28 Brazil Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 29 Argentina Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 30 Middle East & Africa Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 31 Middle East & Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 32 South Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 33 Saudi Arabia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 34 UAE Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 35 Kuwait Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
LIST OF FIGURES


Fig. 1 Construction nails market segmentation
Fig. 2 Information Procurement
Fig. 3 Data Analysis Models
Fig. 4 Market Formulation and Validation
Fig. 5 Data Validating & Publishing
Fig. 6 Regional Outlook
Fig. 7 Segmental Outlook
Fig. 8 Competitive Outlook
Fig. 9 Global Industrial Fasteners Market, 2023 (USD Billion)
Fig. 10 Construction Nails market - Value chain analysis
Fig. 11 U.S. Stainless Steel Price Trend, 2019-2023 (USD/Ton)
Fig. 12 Market driver impact analysis
Fig. 13 U.S. construction industry spending, 2018-2023 (USD Million)
Fig. 14 Market restraints impact analysis
Fig. 15 Industry Analysis: Porter’s
Fig. 16 PESTEL analysis, by SWOT
Fig. 17 Material: Key Takeaways
Fig. 18 Material: Market Share, 2023 & 2030
Fig. 19 Stainless steel construction nails market estimates & forecasts, 2018 - 2030 (USD Billion)
Fig. 20 Carbon steel construction nails market estimates & forecasts, 2018 - 2030 (USD Billion)
Fig. 21 Construction nails market estimates & forecasts, by others, 2018 - 2030 (USD Billion)
Fig. 22 Application: Key Takeaways
Fig. 23 Application: Market Share, 2023 & 2030
Fig. 24 Construction nails market estimates & forecasts, by wood construction, 2018 - 2030 (USD Billion)
Fig. 25 Construction nails market estimates & forecasts, by concrete construction, 2018 - 2030 (USD Million)
Fig. 26 Region, 2023 & 2030 (USD Million)
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 Regional marketplace: Key takeaways
Fig. 29 North America construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 30 U.S. construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 31 Canada construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 32 Mexico construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 33 Europe construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 34 Germany construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 35 UK construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 36 France construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 37 Spain construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 38 Turkey construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 39 Asia Pacific construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 40 China construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 41 India construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 42 Japan construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 43 South Korea construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 44 Australia construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 45 Central & South America construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 46 Brazil construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 47 Argentina construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 48 Middle East & Africa construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 49 UAE construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 50 Saudi Arabia construction nails market estimates & forecasts, 2018 - 2030 (USD Million)
Fig. 51 Kraljic Matrix
Fig. 52 Engagement Model
Fig. 53 Sourcing Best Practices
Fig. 54 Vendor Selection Criteria
Fig. 55 Competition Categorization
Fig. 56 Company Market Positioning
Fig. 57 Strategy Mapping, 2023


More Publications